MedTrace Logo

Improving Function,Welfare of Late-stage Cancer Subjects by ACC

NCT03057314 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-02-28

No results posted yet for this study

Summary

To improve the function and welfare of late stage solid cancer subjects by:

* enabling subjects to benefit from a potentially promising drug under development
* assessing initial evidence of improvement in Pain VAS score
* assessing initial improvement in Performance Status (PS)
* assessing initial improvement in oxygen saturation whenever it is feasible

Conditions

  • Solid Malignancies, With or Without Lung Metastases

Interventions

DRUG

Amorphous Calcium Carbonate

Subjects will be administered with: 1. ACC tablets, containing 200 mg elemental calcium 2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension

Sponsors & Collaborators

  • Amorphical Ltd.

    lead INDUSTRY

Principal Investigators

  • Julia Rothman, Dr. · Head of clinical affairs

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-25
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03057314 on ClinicalTrials.gov